121 results
DEFA14A
IBRX
ImmunityBio Inc
29 Apr 24
Additional proxy soliciting materials
4:20pm
, M.D. For 1h. Christobel Selecky For 1i. Barry J. Simon, M.D. For 2. To approve an amendment to the Immunity Bio, Inc. 2015 Equity Incentive Plan
8-K
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
in situ with or without papillary tumors.
Potential Increase in Shares Authorized for Issuance under the ImmunityBio, Inc. 2015 Equity Incentive Plan … to the ImmunityBio, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance
S-3ASR
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
.
To the extent that options are exercised, new options are issued under our equity incentive plans, or we issue additional shares of common stock
8-K
y3exc5uw
23 Feb 24
Departure of Directors or Certain Officers
9:28pm
424B5
84b4ult eaq6ne
24 Jul 23
Prospectus supplement for primary offering
5:12pm
8-K
EX-10.1
c48mnkw x6eoa
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-1.1
f2uwcv403entcish
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
EX-10.1
l0z88o4 38280d4n0f
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
EX-1.1
t8755i6dpu3f4d8xkwr
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
424B5
q6ckk
12 Dec 22
Prospectus supplement for primary offering
8:08am